On Friday, Marinus Pharmaceuticals Incs drug ‘Ztalmy’ received approval from the U.S. Food and Drug Administration for the treatment of seizures linked with a rare genetic disorder. The drug has been approved for use in patients two years of age and older.

The oral drug is indicated for seizures associated with CDKL5 deficiency disorder, a rare form of genetic epilepsy. The regulatory approval was based on a late-stage study that included 101 patients. It showed a mean reduction of 30.7% in 28-day major motor seizure frequency in the drug-treated group compared to the placebo group.

Chief Executive Officer Scott Braunste in said that the drug would cost around $133,000 per patient per year at the wholesale level and the discounted amount would be $105,000 per patient per year, including for Medicaid patients.Itwas expected to be available in the U.S.commercially in July.

(ET HeathWorld – Reuters, March 19,2022)